Effect of Short-term Erythropoietin Therapy on Insulin Resistance and Serum Levels of Leptin and Neuropeptide Y in Hemodialysis Patients

Overview

Journal Indian J Endocrinol Metab

Specialty Endocrinology

Date 2017 Oct 10

PMID 28989882

Citations 1

Authors

Hamed M Osman

Osama A Khamis

Mohamed S Elfeky

Amani M El Amin Ali

Mostafa Y Abdelwahed

Affiliations

Soon will be listed here.

Abstract

Introduction: Insulin resistance (IR) is a known complication of end-stage kidney disease (ESKD). It may be an important therapeutic target in stages of chronic kidney disease.

Aim: The study was conducted to evaluate the effect of short-term treatment with recombinant human erythropoietin (rHuEpo) therapy on IR, serum leptin, and neuropeptide Y in ESKD patients on hemodialysis.

Materials And Methods: Thirty ESKD patients were enrolled in the study and were randomly assigned into two groups. Erythropoietin (rHuEpo) group consisted of 15 patients (7 females, 8 males, mean age 47.8 ± 9.3 years) treated with rHuEpo therapy after each session of dialysis. No-rHuEpo group consisted of 15 patients (7 females, 8 males, mean age 45.5 ± 8.6 years) not treated with rHuEpo. In addition to, control group consisted of 15 healthy controls (6 females, 9 males, mean age 48.8 ± 11 years).

Results: The mean fasting insulin (11 ± 4.2 mU/L) and homeostatic model assessment of IR (HOMA-IR) test (2.6 ± 1.1) were significantly higher in ESKD patients than control group (6.6 ± 1.4 mU/L and 1.5 ± 0.3, respectively). There were significant decreases in glycated hemoglobin (HbA1c) (5.6 ± 1%), fasting insulin level (9.3 ± 3.1 μU/mL), HOMA-IR (2.2 ± 0.7), and serum leptin levels (17.4 ± 8.7 ng/mL) also significant increase in neuropeptide Y levels (113 ± 9.9 pg/mL) after 3 months of rHuEpo therapy, in addition to further significantly decrease fasting insulin levels (7.1 ± 2.1 μU/mL) and HOMA-IR (1.7 ± 6) after 6 months in rHuEpo group. In contrast, there were significantly increases in HbA1c% (5.9 ± 0.5%) and leptin levels (42.3 ± 25.3 ng/mL) in No-rHuEpo group throughout the study.

Conclusion: IR and hyperleptinemia are improved by recombinant human erythropoietin therapy.

Citing Articles

The Many Facets of Erythropoietin Physiologic and Metabolic Response.

Suresh S, Rajvanshi P, Noguchi C Front Physiol. 2020; 10:1534.

PMID: 32038269 PMC: 6984352. DOI: 10.3389/fphys.2019.01534.

References

Yilmaz A, Kayardi M, Icagasioglu S, Candan F, Nur N, Gultekin F . Relationship between serum leptin levels and body composition and markers of malnutrition in nondiabetic patients on peritoneal dialysis or hemodialysis. J Chin Med Assoc. 2005; 68(12):566-70. DOI: 10.1016/s1726-4901(09)70095-4. View

Wesolowski P, Saracyn M, Nowak Z, Wankowicz Z . Insulin resistance as a novel therapeutic target in patients with chronic kidney disease treated with dialysis. Pol Arch Med Wewn. 2010; 120(1-2):54-7. View

Rasic-Milutinovic Z, Perunicic-Pekovic G, Cavala A, Gluvic Z, Bokan L, Stankovic S . The effect of recombinant human erythropoietin treatment on insulin resistance and inflammatory markers in non-diabetic patients on maintenance hemodialysis. Hippokratia. 2008; 12(3):157-61. PMC: 2504398. View

KOKOT F, Wiecek A, Mesjasz J, Adamczak M, Spiechowicz U . Influence of long-term recombinant human erythropoietin (rHuEpo) therapy on plasma leptin and neuropeptide Y concentration in haemodialysed uraemic patients. Nephrol Dial Transplant. 1998; 13(5):1200-5. DOI: 10.1093/ndt/13.5.1200. View

Hager S . Insulin resistance of uremia. Am J Kidney Dis. 1989; 14(4):272-6. DOI: 10.1016/s0272-6386(89)80201-x. View

Cioffi J, Shafer A, Zupancic T, Mikhail A, Platika D, Snodgrass H . Novel B219/OB receptor isoforms: possible role of leptin in hematopoiesis and reproduction. Nat Med. 1996; 2(5):585-9. DOI: 10.1038/nm0596-585. View

Khedr E, El-Sharkawy M, Abdulwahab S, Eldin E, Ali M, Youssif A . Effect of recombinant human erythropoietin on insulin resistance in hemodialysis patients. Hemodial Int. 2009; 13(3):340-6. DOI: 10.1111/j.1542-4758.2009.00367.x. View

Sharma K, Considine R, Michael B, Dunn S, Weisberg L, Kurnik B . Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int. 1997; 51(6):1980-5. DOI: 10.1038/ki.1997.269. View

Gluba A, Mikhailidis D, Lip G, Hannam S, Rysz J, Banach M . Metabolic syndrome and renal disease. Int J Cardiol. 2012; 164(2):141-50. DOI: 10.1016/j.ijcard.2012.01.013. View

10.

Considine R, Sinha M, Heiman M, Kriauciunas A, STEPHENS T, Nyce M . Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996; 334(5):292-5. DOI: 10.1056/NEJM199602013340503. View

11.

Axelsson J, Qureshi A, Heimburger O, Lindholm B, Stenvinkel P, Barany P . Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD. Am J Kidney Dis. 2005; 46(4):628-34. DOI: 10.1053/j.ajkd.2005.06.004. View

12.

Stefanovic V, Djordjevic V, Ivic M, Mitic-Zlatkovic M, Vlahovic P . Lymphocyte PC-1 activity in patients on maintenance haemodialysis treated with human erythropoietin and 1-alpha-D3. Ann Clin Biochem. 2005; 42(Pt 1):55-60. DOI: 10.1258/0004563053026790. View

13.

Stenvinkel P, Heimburger O, Lonnqvist F . Serum leptin concentrations correlate to plasma insulin concentrations independent of body fat content in chronic renal failure. Nephrol Dial Transplant. 1997; 12(7):1321-5. DOI: 10.1093/ndt/12.7.1321. View

14.

Barany P, Pettersson E, Ahlberg M, Hultman E, Bergstrom J . Nutritional assessment in anemic hemodialysis patients treated with recombinant human erythropoietin. Clin Nephrol. 1991; 35(6):270-9. View

15.

Cheng H, Huang J, Chiang C, Yen C, Hung K, Wu K . Metabolic syndrome and insulin resistance as risk factors for development of chronic kidney disease and rapid decline in renal function in elderly. J Clin Endocrinol Metab. 2012; 97(4):1268-76. DOI: 10.1210/jc.2011-2658. View

16.

Campbell P, Mandarino L, Gerich J . Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus. Metabolism. 1988; 37(1):15-21. DOI: 10.1016/0026-0495(88)90023-6. View

17.

Rabkin R, Simon N, Steiner S, Colwell J . Effect of renal disease on renal uptake and excretion of insulin in man. N Engl J Med. 1970; 282(4):182-7. DOI: 10.1056/NEJM197001222820402. View

18.

Parikh N, Hwang S, Larson M, Meigs J, Levy D, Fox C . Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch Intern Med. 2006; 166(17):1884-91. DOI: 10.1001/archinte.166.17.1884. View

19.

Bald M, Gerigk M, Rascher W . Elevated plasma concentrations of neuropeptide Y in children and adults with chronic and terminal renal failure. Am J Kidney Dis. 1997; 30(1):23-7. DOI: 10.1016/s0272-6386(97)90560-6. View

20.

KOKOT F, Wiecek A, Grzeszczak W, Klepacka J, Klin M, Lao M . Influence of erythropoietin treatment on endocrine abnormalities in haemodialyzed patients. Contrib Nephrol. 1989; 76:257-70; discussion 270-2. View